{"id":"W3013447738","doi":"10.1182/blood.2020004856","title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":756,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre intégré universitaire de santé et de services sociaux de l'Est-de-l'Île-de-Montréal; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal","funders":"Genentech","keywords":"Venetoclax; Medicine; Internal medicine; Neutropenia; Febrile neutropenia; Hazard ratio; Chemotherapy regimen; Cytarabine; Adverse effect; Chemotherapy; Surgery; Oncology; Leukemia; Confidence interval; Chronic lymphocytic leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009748676,0.0003598949,0.00233117,0.000157457,0.0001117612,0.0000544436,0.0002536941,0.0002303779,0.0001204794],"category_scores_gemma":[0.01292051,0.0002746775,0.0009749715,0.0002676229,0.0001399807,0.00007345288,0.00005559885,0.000318331,0.00003159709],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003301485,"about_ca_system_score_gemma":0.002148186,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004767361,"about_ca_topic_score_gemma":0.000003936445,"domain_scores_codex":[0.9974532,0.00016374,0.0007705097,0.0005849138,0.0003788449,0.0006488058],"domain_scores_gemma":[0.9947076,0.003473827,0.0002518606,0.0003664266,0.0007444406,0.0004558564],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9580711,0.0003708548,0.000001559768,0.0001860102,0.001649222,0.00006141707,0.001194285,0.00002594233,0.008039362,0.00008849124,0.02929752,0.001014229],"study_design_scores_gemma":[0.9307827,0.004234286,3.433275e-7,0.00005992651,0.001477416,0.00001442153,0.0002562904,0.03879286,0.01462016,0.0001770094,0.009336777,0.0002478371],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8676347,0.00104368,0.02632007,0.02287738,0.0004688317,0.08031385,0.0001876901,0.0003557953,0.0007979897],"genre_scores_gemma":[0.9064168,0.0004829216,0.01526254,0.02602119,0.007801172,0.03992403,0.0005897361,0.0003717248,0.00312983],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04038982,"threshold_uncertainty_score":0.9999706,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0321181257161765,"score_gpt":0.3360420507156437,"score_spread":0.3039239249994672,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}